Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-α inhibitors

Journal of Drugs in Dermatology

Volumn 10, Issue 3, 2011, Pages 280-284

  Chen, Meng ^a   Holland, Michael J ^a   Mir, Mohsin R ^a   Wong, Michael G ^a   Kelley, Brian P ^a   Grim, Kelli D ^a   Bhuchar, Sunaina S ^a   Hsu, Sylvia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIASIS; SEROLOGY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOOD CELL COUNT; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PLATELET COUNT; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80052995215     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. About psoriasis: Statistics. National Psoriasis Foundation Web site. Available at: http://www.psoriasis.org/netcommunity/learn-statistics. Accessed January 2010.
2. Levine D, Gottlieb A. Evaluation and management of psoriasis: An internist's guide. Med Clin North Am. 2009;93(6):1291-1303.
3. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: Current and emerging directed therapies. Ann Rheum Dis. 2005;64(Suppl 2):ii87-90. (Pubitemid 40288531)
4. Brunasso AM, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. J Am Acad Dermatol. 2009;60(5):781-785.
5. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57. (Pubitemid 40432507)
6. Salar A, Bessa X, Muniz E, et al. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease. Gut. 2007;56:1169-1170. (Pubitemid 47123255)
7. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003;139:W62-W63.
8. Kuruvilla J, Leitch HA, Vickars LM, et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol. 2003;71(5):396-398. (Pubitemid 37330515)
9. Stinco G, Piccirillo F, Patrone P. Transient and slight thrombocytopaenia induced by etanercept during treatment of psoriatic arthritis. Acta Derm Venereol. 2008;88:281-282. (Pubitemid 351743878)
10. Pathare SK, Heycock C, Hamilton J. TNF alpha blocker-induced thrombocytopenia. Rheumatology. 2006;45:1313-1314.
11. Hamaguchi M, Kawahito Y, Ishino H, et al. A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol. 2007;26:988-990. (Pubitemid 46951308)
12. Menon Y, Cucurull E, Espinoza R. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology. 2003;42:1273-1274. (Pubitemid 37258503)
13. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008;67:1145-1152.
14. Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: A 12 month observational study of 16 patients. Ann Rheum Dis. 2004;63:156-161. (Pubitemid 38122134)
15. Keystone EC. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:427-443. (Pubitemid 32488715)
16. Jacobsen SE, Jacobsen FW, Fahlman C, Rusten LS. TNF-alpha, the great imitator: Role of p55 and p75 TNF receptors in hematopoiesis. Stem Cells. 1994;12(Suppl 1):111-126.
17. Andres E, Dali-Youcef N, Serraj K, Zimmer J. Recognition and management of drug-induced cytopenias: The example of idiosyncratic drug-induced thrombocytopenia. Expert Opin Drug Saf. 2009;8(2):183-190.
18. Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am. 2007;21(4):685-696. (Pubitemid 47102560)
19. George JN, Aster RH. Drug-induced thrombocytopenia: Pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009:153-158.
20. Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and drug- specific"antibodies. Blood. 2006;108:922-927. (Pubitemid 44154626)
21. Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GP IIIa. Blood. 2008;111:1234-1239. (Pubitemid 351213405)
22. Caramaschi P, Bambara LM, Pieropan S, et al. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine. 2009;76(4):333-342.
23. Kocharla L, Mongey AB. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus. 2009;18(2):169-171.
24. Burgess JK. Molecular mechanisms of drug-induced thrombocytopenia. Curr Opin Hematol. 2001;8(5):294-298. (Pubitemid 32826499)
25. Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv Hematol. 2009;2009:495863. Epub 2009 July 7.
26. Litton G. Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept. Am J Hematol. 2008;83(4):344. (Pubitemid 351458021)
27. McMinn JR Jr, Cohen S, Moore J, et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol. 2003;73:135-140. (Pubitemid 36578437)
28. Lazaraki G, Metallidis S, Giannoulis K, et al. Infliximab: An alternative treatment for refractory immune thrombocytopenic purpura related to Crohn's disease? Inflamm Bowel Dis. 2007;13:1452-1453. (Pubitemid 350206865)
29. DeRycke L, Baeten D, Kruithof E, et al. Infliximab, but not etanercept, induces IgM antidouble-stranded DNA antibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005;52:2192-2201. (Pubitemid 40994342)
30. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008;117:244-279.